---
layout: post
title: "Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal"
date: 2026-02-05 19:01:51 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-27022
original_published: 2022-12-14 00:00:00 +0000
significance: 8.00
---

# Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** December 14, 2022 00:00 UTC
**Document Number:** 2022-27022

## Summary

The Food and Drug Administration (FDA) is announcing the renewal of the Endocrinologic and Metabolic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Endocrinologic and Metabolic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2024, expiration date.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/12/14/2022-27022/advisory-committee-endocrinologic-and-metabolic-drugs-advisory-committee-renewal)
- API: https://www.federalregister.gov/api/v1/documents/2022-27022

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
